Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.

Lukas RobDavid CibulaPawel KnappPeter MallmannJaroslav KlatLubos MinarPavel BartosJosef ChovanecPetr ValhaMarek PlutaZdenek NovotnyJiri SpacekBohuslav MelicharDariusz KieszkoJitka FucikovaTereza HrnciarovaRoman Pawel KorolkiewiczMarek HraskaJirina BartunkovaRadek Spisek

Published in: Journal for immunotherapy of cancer (2022)

NCT02107937, EudraCT2010-021462-30.

Keyphrases

dendritic cells
open label
phase ii study
phase iii
locally advanced
chemotherapy induced
clinical trial
regulatory t cells
phase ii
double blind
immune response
rectal cancer
study protocol
cross sectional
squamous cell carcinoma
radiation therapy
placebo controlled
randomized controlled trial